|
US4903164A
(en)
|
1988-12-08 |
1990-02-20 |
Texas Instruments Incorporated |
O-ring/back-up ring seal for high pressure transducers
|
|
EP1577816A3
(en)
*
|
1996-09-04 |
2006-08-02 |
Intertrust Technologies Corp. |
Trusted infrastructure support systems, methods and techniques for secure electronic commerce and rights management
|
|
EP2081905B1
(en)
|
2006-07-28 |
2012-09-12 |
Boehringer Ingelheim International GmbH |
Sulfonyl compounds which modulate the cb2 receptor
|
|
KR101435231B1
(ko)
|
2006-08-24 |
2014-10-02 |
아스트라제네카 아베 |
증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
|
|
US7928123B2
(en)
|
2006-09-25 |
2011-04-19 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the CB2 receptor
|
|
AU2008205252B2
(en)
*
|
2007-01-09 |
2013-02-21 |
Amgen Inc. |
Bis-aryl amide derivatives useful for the treatment of cancer
|
|
KR20090108124A
(ko)
*
|
2007-02-06 |
2009-10-14 |
노파르티스 아게 |
Ｐｉ 3-키나제 억제제 및 그의 사용 방법
|
|
US8138183B2
(en)
*
|
2007-07-09 |
2012-03-20 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
|
|
KR20100031639A
(ko)
*
|
2007-07-09 |
2010-03-23 |
아스트라제네카 아베 |
증식성 질환의 치료용 삼중 치환된 피리미딘 유도체
|
|
CA2704684A1
(en)
|
2007-11-07 |
2009-05-14 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
EP2250160B1
(en)
|
2008-01-25 |
2015-11-11 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
|
|
WO2009110985A2
(en)
|
2008-02-29 |
2009-09-11 |
Renovis, Inc. |
Amide compounds, compositions and uses thereof
|
|
CA2724232A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Boehringer Ingelheim International Gmbh |
Sulfone compounds which modulate the cb2 receptor
|
|
DK3216793T3
(da)
|
2008-05-23 |
2019-05-06 |
Wyeth Llc |
Triazinforbindelser som p13-kinase- og mtor-inhibitorer
|
|
NZ589844A
(en)
*
|
2008-06-19 |
2012-11-30 |
Millennium Pharm Inc |
Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
|
|
WO2010005782A1
(en)
|
2008-07-10 |
2010-01-14 |
Boehringer Ingelheim International Gmbh |
Sulfone compounds which modulate the cb2 receptor
|
|
AU2009276339B2
(en)
|
2008-07-31 |
2012-06-07 |
Genentech, Inc. |
Pyrimidine compounds, compositions and methods of use
|
|
EP2342191B1
(en)
|
2008-09-10 |
2013-03-20 |
Mitsubishi Tanabe Pharma Corporation |
Aromatic nitrogen-containing 6-membered ring compounds and their use
|
|
EP2346825A2
(en)
|
2008-09-18 |
2011-07-27 |
Evotec AG |
Modulators of p2x3 receptor activity
|
|
EA201100523A1
(ru)
|
2008-09-25 |
2011-10-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Соединения сульфонила, которые селективно модулируют рецептор св2
|
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
|
UY32351A
(es)
|
2008-12-22 |
2010-07-30 |
Astrazeneca Ab |
Compuestos de pirimidinil indol para uso como inhibidores de atr
|
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
|
US9139589B2
(en)
|
2009-01-30 |
2015-09-22 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US8796314B2
(en)
|
2009-01-30 |
2014-08-05 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US8785457B2
(en)
|
2009-03-13 |
2014-07-22 |
Cellzome Limited |
Pyrimidine derivatives as mTOR inhibitors
|
|
WO2010120991A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
|
|
CA2755554C
(en)
*
|
2009-04-17 |
2013-09-24 |
Wyeth Llc |
Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
WO2010120996A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
JPWO2010125799A1
(ja)
*
|
2009-04-27 |
2012-10-25 |
塩野義製薬株式会社 |
Ｐｉ３ｋ阻害活性を有するウレア誘導体
|
|
US8299103B2
(en)
|
2009-06-15 |
2012-10-30 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the CB2 receptor
|
|
US8383615B2
(en)
|
2009-06-16 |
2013-02-26 |
Boehringer Ingelheim International Gmbh |
Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
|
|
KR102050712B1
(ko)
|
2009-06-17 |
2019-12-02 |
버텍스 파마슈티칼스 인코포레이티드 |
인플루엔자 바이러스 복제의 억제제
|
|
SG176959A1
(en)
*
|
2009-06-24 |
2012-01-30 |
Genentech Inc |
Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
|
|
WO2011037795A1
(en)
|
2009-09-22 |
2011-03-31 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the cb2 receptor
|
|
PH12012500809A1
(en)
|
2009-10-30 |
2012-11-26 |
Ariad Pharma Inc |
Methods and compositions for treating cancer
|
|
CN102711766B
(zh)
|
2009-11-12 |
2014-06-04 |
霍夫曼-拉罗奇有限公司 |
N-9-取代的嘌呤化合物、组合物和使用方法
|
|
US8828990B2
(en)
|
2009-11-12 |
2014-09-09 |
Genentech, Inc. |
N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
|
|
US9315491B2
(en)
|
2009-12-28 |
2016-04-19 |
Development Center For Biotechnology |
Pyrimidine compounds as mTOR and PI3K inhibitors
|
|
WO2011088015A1
(en)
|
2010-01-15 |
2011-07-21 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
WO2011107585A1
(en)
|
2010-03-04 |
2011-09-09 |
Cellzome Limited |
Morpholino substituted urea derivatives as mtor inhibitors
|
|
US8329735B2
(en)
|
2010-03-05 |
2012-12-11 |
Boehringer Ingelheim International Gmbh |
Tetrazole compounds which selectively modulate the CB2 receptor
|
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
|
JP5746764B2
(ja)
|
2010-07-22 |
2015-07-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を調節する化合物
|
|
US9062038B2
(en)
|
2010-08-11 |
2015-06-23 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
WO2012021615A1
(en)
|
2010-08-11 |
2012-02-16 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US8796268B2
(en)
|
2010-08-11 |
2014-08-05 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
CN103140479B
(zh)
|
2010-10-01 |
2015-04-08 |
诺华有限公司 |
制造嘧啶衍生物的方法
|
|
AU2011316016A1
(en)
|
2010-10-13 |
2013-05-30 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US8440662B2
(en)
|
2010-10-31 |
2013-05-14 |
Endo Pharmaceuticals, Inc. |
Substituted quinazoline and pyrido-pyrimidine derivatives
|
|
JP2014510122A
(ja)
|
2011-04-04 |
2014-04-24 |
セルゾーム リミテッド |
ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
|
|
CN102887867B
(zh)
*
|
2011-07-21 |
2015-04-15 |
中国科学院上海药物研究所 |
一类三嗪类化合物、该化合物的制备方法及其用途
|
|
BR112014001880A2
(pt)
*
|
2011-07-26 |
2017-02-21 |
Gruenenthal Gmbh |
derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide
|
|
UA118010C2
(uk)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
Інгібітори реплікації вірусів грипу
|
|
WO2013030665A1
(en)
*
|
2011-09-02 |
2013-03-07 |
Purdue Pharma L.P. |
Pyrimidines as sodium channel blockers
|
|
CA2849189A1
(en)
|
2011-09-21 |
2013-03-28 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mtor inhibitors
|
|
CN103946222B
(zh)
|
2011-10-07 |
2016-12-28 |
塞尔佐姆有限公司 |
作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物
|
|
CN104350144B
(zh)
|
2012-05-23 |
2017-08-04 |
弗·哈夫曼-拉罗切有限公司 |
获得和使用内胚层和肝细胞的组合物和方法
|
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
|
US9296727B2
(en)
|
2013-10-07 |
2016-03-29 |
Vertex Pharmaceuticals Incorporated |
Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
|
|
KR102338461B1
(ko)
|
2013-11-13 |
2021-12-13 |
버텍스 파마슈티칼스 인코포레이티드 |
인플루엔자 바이러스 복제 억제제의 제조 방법
|
|
PL3068776T3
(pl)
|
2013-11-13 |
2019-10-31 |
Vertex Pharma |
Inhibitory replikacji wirusów grypy
|
|
CN106458921B
(zh)
*
|
2014-05-21 |
2020-03-24 |
阿勒根公司 |
作为甲酰肽受体调节剂的咪唑衍生物
|
|
CA2957046C
(en)
|
2014-08-04 |
2022-11-15 |
Nuevolution A/S |
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
|
|
EP3294717B1
(en)
|
2015-05-13 |
2020-07-29 |
Vertex Pharmaceuticals Inc. |
Methods of preparing inhibitors of influenza viruses replication
|
|
MA42422A
(fr)
|
2015-05-13 |
2018-05-23 |
Vertex Pharma |
Inhibiteurs de la réplication des virus de la grippe
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
EP3630116B1
(en)
|
2017-05-26 |
2024-05-01 |
The Board Of Regents Of The University Of Texas System |
Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
|
|
IL271930B
(en)
|
2017-07-13 |
2022-07-01 |
Univ Texas |
Heterocyclic inhibitors of atr kinase
|
|
US10800774B2
(en)
|
2017-08-17 |
2020-10-13 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of ATR kinase
|
|
CN112218631B
(zh)
|
2018-03-16 |
2023-12-22 |
德州大学系统董事会 |
Atr激酶的杂环抑制剂
|
|
US11685727B2
(en)
|
2019-12-20 |
2023-06-27 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
WO2021124277A1
(en)
|
2019-12-20 |
2021-06-24 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
EP4126874A1
(en)
|
2020-03-31 |
2023-02-08 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
AU2021249530A1
(en)
|
2020-03-31 |
2022-12-01 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|